Normunity

Normunity is a private, preclinical-to-clinical stage biotech founded in 2021 and based in New Haven, CT, focused on oncology and immunology. The company's core innovation is its discovery platform, born from a deep, ongoing partnership with the Lieping Chen lab at Yale, which identifies novel 'Immuno-smart' targets that are both tumor-specific and central to immune evasion. This approach has yielded a pipeline of biologic therapies, led by NRM-823, a T cell engager that has recently entered clinical development. Led by CEO Rachel Humphrey, a veteran developer of major cancer immunotherapies, Normunity aims to create a new generation of medicines that free normal immunity to defeat a broad array of solid tumors.

Proprietary discovery platforms, developed in partnership with the Lieping Chen lab at Yale, that interrogate tumor-immune system interactions to identify 'Immuno-smart' targets—tumor-specific, cell-surface proteins co-opted by cancer to drive local immune suppression.

Normunity competes in the next-generation immuno-oncology space, vying against numerous biotechs and large pharma companies developing novel immune modulators, bispecific antibodies, and cell therapies. Its differentiation lies in its unique target discovery platform and focus on tumor-specific immune suppressive mechanisms, a niche distinct from broadly expressed checkpoints like PD-1.